33545-40-3

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 5-(2-FURYL)ISOXAZOLE-3-CARBOXYLATE is used as a key intermediate in the synthesis of pharmaceutical drugs. Its unique isoxazole ring structure contributes to the development of new medications with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 5-(2-FURYL)ISOXAZOLE-3-CARBOXYLATE serves as a crucial component in the production of agrochemicals. Its incorporation aids in the creation of effective compounds for pest control and crop protection.
Used in Coordination Chemistry:
ETHYL 5-(2-FURYL)ISOXAZOLE-3-CARBOXYLATE is used as a ligand in coordination chemistry. Its ability to form stable complexes with metal ions is valuable for the development of new materials with specific properties and applications.
Used in Synthesis of Biologically Active Molecules:
ETHYL 5-(2-FURYL)ISOXAZOLE-3-CARBOXYLATE is also utilized in the synthesis of biologically active molecules. Its presence in these molecules can enhance their biological activity, making them more effective in various applications, such as drug discovery and development.

InChI:InChI=1/C10H9NO4/c1-2-13-10(12)7-6-9(15-11-7)8-4-3-5-14-8/h3-6H,2H2,1H3

Upstream product

• 36983-35-4 ethyl 4-(furan-2-yl)-2,4-dioxobutyrate 
• 1192-62-7 1-(2-furyl)-1-ethanone 
• 33008-49-0 4-furan-2-yl-4-oxo-but-2-ynoic acid ethyl ester 

Downstream Products

• 98434-06-1 5-(furan-2-yl)-1,2-oxazole-3-carboxylic acid 
• 58589-69-8 3-(furan-2-yl)-1-phenyl-1H-pyrazol-5-amine 
• 90110-76-2 5-furan-2-yl-isoxazole-3-carboxylic acid hydrazide 
• 852180-63-3 (5-furan-2-yl-isoxazol-3-yl)-methanol 

Relevant academic research and scientific papers

Synthesis of isoxazoles via cyclization of β-fluoro enones with sodium azide

A practical method for the synthesis of 3,5-disubstituted isoxazoles via cyclization of β-fluoro enones with sodium azide was disclosed. Density functional theory (DFT) calculation indicated that both (1) the azirine formation followed by intramolecular rearrangement and (2) direct enolate O-attack via 5-exo-trig cyclization of vinyl azide were possible for the isoxazole formation.

Development of a continuous flow photoisomerization reaction converting isoxazoles into diverse oxazole products

A continuous flow process is presented, which directly converts isoxazoles into their oxazole counterparts via a photochemical transposition reaction. This results in the first reported exploitation of this transformation to establish its scope and synthe

ATF6 INHIBITORS AND USES THEREOF

Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.

PHARMACEUTICAL COMPOSITION FOR PREVENTINTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES

There is provided a pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives. The pharmaceutical composition includes a therapeutic effective amount of isoxazole derivatives represented by Formula 1 or pharmaceutically available salts thereof. The pharmaceutical composition may be useful to prevent and treat vascular restenosis since the pharmaceutical composition shows an anti-restenosis activity and accelerates the re-endothelization.

ISOXAZOLE DERIVATIVES AND USE THEREOF

Disclosed herein are isoxazole derivatives and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/beta-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed

ISOXAZOLE DERIVATIVES AND USE THEREOF

Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.